SALUS promet s farmacevtskimi, medicinskimi in drugimi proizvodi, d.d., Ljubljana (E3U.F)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in EUR.

Revenue Annual

0 250M 500M 750M Q4 '19: 348M Q4 '20: 400.7M Q4 '21: 458.3M Q4 '22: 495.7M Q4 '23: 599.4M Q4 '24: 648.8M Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24

Gross Profit Annual

0 25M 50M 75M Q4 '19: 37.1M Q4 '20: 45.3M Q4 '21: 53.5M Q4 '22: 53.8M Q4 '23: 60.2M Q4 '24: 73.5M Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24

Operating Income Annual

0 6M 12M 18M Q4 '19: 7.9M Q4 '20: 12.3M Q4 '21: 15.3M Q4 '22: 16M Q4 '23: 13.2M Q4 '24: 16.7M Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24

Net Income Annual

0 5M 10M 15M Q4 '19: 5.9M Q4 '20: 10.1M Q4 '21: 13M Q4 '22: 13.1M Q4 '23: 10.4M Q4 '24: 13M Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

0 8M 16M 24M Q4 '19: 6.4M Q4 '20: 5.3M Q4 '21: 22.9M Q4 '22: 11.6M Q4 '23: 21.7M Q4 '24: 12.1M Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24

Free Cash Flow Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.